The MAP-AD® Test is a qualitative in vitro diagnostic (IVD) blood test for the prognosis of the progression from Mild Cognitive Impairment to AD dementia in adult patients between 55 and 85 years old...
Read moreCon motivo del Día Mundial del Alzheimer, hablamos con Marta Barrachina, fundadora y directora general de ADmit Therapeutics, uno de nuestros socios que busca un diagnóstico precoz a esta enfermedad...
Read moreDespite the Covid-19 pandemic, 2020 has been a great year for ADmit Therapeutics, a spin-off from Bellvitge Biomedical Research Institute (IDIBELL, in Barcelona) born at the end of 2017 and leaded by ...
Read moreLa spin-of del IDIBELL, creada en 2017 y con sede en L'Hospitalet de Llobregat, es una de las 36 empresas seleccionadas de entre las 1.406 solicitudes recibidas en la convocatoria EIC Accelerator del ...
Read moreThe SARS-CoV-2 pandemic that is hitting many countries has clearly affected the medical start-up and spin-off ecosystem. After talking to some of the companies we support we have seen that it has not ...
Read moreADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnost...
Read moreADmit Therapeutics has received an investment of 497.652$ from the ADDF Diagnostics Accelerator for the development of its early Alzheimer’s disease diagnostic test in blood samples. The Diagnost...
Read more